Welcome to our dedicated page for Virax Biolabs Group news (Ticker: VRAX), a resource for investors and traders seeking the latest updates and insights on Virax Biolabs Group stock.
Virax Biolabs Group Limited reports developments in immunology research and diagnostics, with a focus on immune response detection and post-acute infection syndromes. Company updates center on the in-development ViraxImmune T cell immune-profiling platform, PAIS-related conditions such as Long COVID, post-treatment Lyme disease and ME/CFS, and the ImmuneSelect research-use-only product portfolio.
Recurring news themes include clinical study activity, research collaborations, regulatory and quality-system preparation, commercial planning for immune-profiling products, private placements and other capital-structure actions. Updates also cover board composition, shareholder communications and Nasdaq listing-compliance matters for the company’s ordinary shares.
Virax Biolabs (NASDAQ: VRAX) announced that CEO James Foster presented at H.C. Wainwright's 24th Annual Global Investment Conference in New York from September 12-14, 2022. The presentation is available on-demand. Virax is focused on innovative biotechnology solutions, particularly immunology profiling against viral diseases. The company is developing T-Cell Test technology for diagnosing and assessing immune risks related to COVID-19 and other viral threats like Monkeypox and Hepatitis B.
Virax Biolabs Group Limited (Nasdaq: VRAX), a biotech company focused on viral disease detection, announced that its CEO, James Foster, will present at H.C. Wainwright's 24th Annual Global Investment Conference from September 12-14, 2022, in New York, NY. The presentation will be available on-demand starting September 12 at 7:00 AM EST. Virax specializes in T-Cell Test technology for assessing immune risk profiles against major viral threats, including COVID-19 and Monkeypox. The company aims to enhance immunity profiling in viral disease management.
Summary not available.
Virax Biolabs Group Limited (Nasdaq: VRAX) has launched its Monkeypox and Varicella-Zoster PCR Detection Kits, now available in Europe. This initiative follows the significant global Monkeypox outbreak, with over 6,000 confirmed cases as of July 4, 2022. The kits aim to provide rapid diagnosis of these viral infections, supporting timely treatment. CEO James Foster highlighted the importance of swift detection for public health, particularly in light of lessons learned from COVID-19. Virax continues to focus on innovative diagnostics, further expanding its product portfolio.
Virax Biolabs Group Limited (Nasdaq: VRAX) completed its initial public offering (IPO), trading began on the Nasdaq Capital Market on July 21, 2022. The IPO included 1,350,000 shares at $5.00 each, raising total gross proceeds of $6.75 million. Boustead Securities, LLC acted as the underwriter for this offering. The funds are expected to support the development of their proprietary T-Cell Test technology aimed at diagnosing viral diseases, particularly COVID-19 and other viral threats.